Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience (NAGE) with a Buy rating and $13 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Biosciences Reports Strong Q1 2025 Growth
- Niagen Bioscience’s Clinical Expansion and Strong Financial Performance Drive Buy Rating
- Niagen Bioscience Reports Strong Q1 2025 Growth
- Closing Bell Movers: Arm sinks over 10% as guidance falls short
- Niagen Bioscience Reports Strong Q1 2025 Financial Results